Published in Cell Discov on October 27, 2015
Vemurafenib and trametinib reduce expression of CTGF and IL-8 in (V600E)BRAF melanoma cells. Lab Invest (2017) 0.80
The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cells. Oncogenesis (2017) 0.78
Cuprous oxide nanoparticle-inhibited melanoma progress by targeting melanoma stem cells. Int J Nanomedicine (2017) 0.75
Role of RAD51AP1 in homologous recombination DNA repair and carcinogenesis. DNA Repair (Amst) (2017) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Identification of cells initiating human melanomas. Nature (2008) 8.28
A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res (2005) 7.86
Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature (2010) 5.05
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature (2013) 4.90
Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev (2000) 4.07
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature (2012) 3.83
The MAPK pathway in melanoma. Curr Opin Oncol (2008) 2.80
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov (2014) 2.51
Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res (2011) 2.08
Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis (2011) 1.76
In vitro and in vivo anti-melanoma effects of ciglitazone. J Invest Dermatol (2009) 1.67
The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα. Cancer Discov (2014) 1.38
The IκB kinase complex in NF-κB regulation and beyond. EMBO Rep (2013) 1.32
Mitochondrial oxidative stress is the Achille's heel of melanoma cells resistant to Braf-mutant inhibitor. Oncotarget (2013) 1.24
Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. Mol Cancer Ther (2013) 1.24
Cell-selective inhibition of NF-κB signaling improves therapeutic index in a melanoma chemotherapy model. Cancer Discov (2011) 1.08
PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget (2014) 0.94
The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells. PLoS One (2014) 0.92
Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth. Cell Death Differ (2010) 0.92
CD271 is an imperfect marker for melanoma initiating cells. Oncotarget (2014) 0.86
A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene (2014) 0.86